Industry News
If you're interested in having us publish a feature article about your organization, a recent transaction or key leadership individuals please contact Dan at dan@partner-rx.com. We will work with you to develop the content, post the article on our website and use our social media (Facebook, Twitter and Linked In) to circulate to the key constituents of your business.
Piramal Acquires Anesthesia and Pain Business from Janssen
Piramal Enterprises has acquired five anesthesia & pain management injectable products from Janssen Pharmaceutica NV, in an all-cash deal. The transaction includes an upfront consideration of $155MM and up to an additional $20MM due in milestones over the next 30 months.
Allergan and Regeneron Ink Deals with Hydrogel technology companies
Allergan licensed global rights to Israel’s UroGen Pharma's RTGel delivery system technology for use with its neurotoxin.
St. Jude and Abbott divest medical devices for $1.12 billion
Abbott Laboratories, which is in the process of buying St. Jude Medical Inc for $25 billion, said the companies would sell some of their medical devices to Japan-based Terumo Corp for about $1.12 billion.
Johnson & Johnson Innovation Announces New Collaboration with Texas Medical Center to Spur Development of Breakthrough Medical Device Technologies
Johnson & Johnson Innovation LLC (JJI) today announced the creation of the Center for Device Innovation at Texas Medical Center (CDI @ TMC), a broad, new collaboration between JJI and TMC that aims to accelerate end-to-end development of breakthrough medical devices. This expands on JJI's collaboration with TMC established earlier this year with the opening of JLABS @ TMC, combining the resources of the world's largest medical complex with the capabilities of the Johnson & Johnson Medical Device
Lilly plans $90 million investment to improve health care in poor areas
Eli Lilly and Co. wants to improve access to health care for 30 million people in impoverished areas around the world. Lilly will invest $90 million in the program to provide better access to treatment for diabetes, cancer and tuberculosis. The five-year investment, called Lilly 30x30, will go to Brazil, China, India, Kenya, Mexico, Russia and South Africa. Lilly also plans to spend some of that money on treating diabetes in Indianapolis.
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules
Bristol-Myers Squibb & Enterome SA , a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-d
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
Kura Oncology, Inc a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the presentation of preclinical data for KO-947, its development candidate targeting the ERK1/2 kinases, and KO-539, its development candidate targeting the menin-MLL interaction, at the American Association for Cancer Research (AACR) Annual Meeting 2017.
Partner Rx: Simplifying The Business Development Process & Driving Results In M&A For Life Science Companies
https://www.superbcrew.com/partner-rx-simplifying-the-business-development-process-driving-results-in-ma-for-life-science-companies/